ADAM10 and neoplasm: The observed functional synergy between tRF-3021a, ADAM10, and sMICA suggests a coordinated axis that facilitates immune evasion and tumor growth, positioning tRF-3021a as a potential therapeutic target for disrupting this pathogenic cascade.